Reported Earnings • Jul 27
First quarter 2027 earnings released: EPS: ₹2.48 (vs ₹8.06 in 1Q 2026) First quarter 2027 results: EPS: ₹2.48 (down from ₹8.06 in 1Q 2026). Revenue: ₹159.6m (down 12% from 1Q 2026). Net income: ₹2.98m (down 69% from 1Q 2026). Profit margin: 1.9% (down from 5.3% in 1Q 2026). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 2% per year. Announcement • Jul 16
Mercury Laboratories Limited to Report Q1, 2027 Results on Jul 25, 2026 Mercury Laboratories Limited announced that they will report Q1, 2027 results at 9:15 AM, Indian Standard Time on Jul 25, 2026 Reported Earnings • May 30
Full year 2026 earnings released: EPS: ₹40.28 (vs ₹26.21 in FY 2025) Full year 2026 results: EPS: ₹40.28 (up from ₹26.21 in FY 2025). Revenue: ₹778.9m (up 3.7% from FY 2025). Net income: ₹48.3m (up 54% from FY 2025). Profit margin: 6.2% (up from 4.2% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat. Announcement • May 30
Mercury Laboratories Limited Recommends Dividend for the Financial Year Ended March 31, 2026 Merc Mercury Laboratories Limited announced that at its meeting held May 29, 2026, The Board of Directors has recommended final dividend @ 35% (INR 3.50 per share) on the Equity Share Capital for the Financial Year Ended March 31, 2026 subject to approval of shareholders at an ensuing Annual General Meeting. Announcement • May 29
Mercury Laboratories Limited, Annual General Meeting, Sep 28, 2026 Mercury Laboratories Limited, Annual General Meeting, Sep 28, 2026. Valuation Update With 7 Day Price Move • May 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹888, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.3% over the past three years. Announcement • May 23
Mercury Laboratories Limited to Report Q4, 2026 Results on May 29, 2026 Mercury Laboratories Limited announced that they will report Q4, 2026 results at 9:15 AM, Indian Standard Time on May 29, 2026 New Risk • May 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.8% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.3m). Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹700, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 21% over the past three years. New Risk • Mar 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹936.5m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 2.8% per year over the past 5 years. Market cap is less than US$10m (₹936.5m market cap, or US$9.99m). Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Feb 12
Third quarter 2026 earnings released: EPS: ₹8.31 (vs ₹9.94 in 3Q 2025) Third quarter 2026 results: EPS: ₹8.31 (down from ₹9.94 in 3Q 2025). Revenue: ₹186.6m (down 4.6% from 3Q 2025). Net income: ₹9.98m (down 16% from 3Q 2025). Profit margin: 5.3% (down from 6.1% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Feb 04
Mercury Laboratories Limited to Report Q3, 2026 Results on Feb 11, 2026 Mercury Laboratories Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026 Reported Earnings • Nov 12
Second quarter 2026 earnings released: EPS: ₹13.69 (vs ₹4.17 in 2Q 2025) Second quarter 2026 results: EPS: ₹13.69 (up from ₹4.17 in 2Q 2025). Revenue: ₹198.0m (up 8.8% from 2Q 2025). Net income: ₹16.4m (up 228% from 2Q 2025). Profit margin: 8.3% (up from 2.8% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Nov 05
Mercury Laboratories Limited to Report Q2, 2026 Results on Nov 11, 2025 Mercury Laboratories Limited announced that they will report Q2, 2026 results on Nov 11, 2025 Announcement • Aug 14
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2025 Merc Mercury Laboratories Limited announced that at its AGM held on August 13, 2025, the shareholders approved declaration of Dividend of INR 3.50/- per equity share of INR 10/- each for the Financial Year ended March 31, 2025. Announcement • Aug 06
Mercury Laboratories Limited to Report Q1, 2026 Results on Aug 13, 2025 Mercury Laboratories Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Upcoming Dividend • Jul 30
Upcoming dividend of ₹3.50 per share Eligible shareholders must have bought the stock before 06 August 2025. Payment date: 11 September 2025. Payout ratio is a comfortable 13% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Reported Earnings • Jul 23
Full year 2025 earnings released: EPS: ₹26.21 (vs ₹47.12 in FY 2024) Full year 2025 results: EPS: ₹26.21 (down from ₹47.12 in FY 2024). Revenue: ₹751.0m (flat on FY 2024). Net income: ₹31.4m (down 44% from FY 2024). Profit margin: 4.2% (down from 7.5% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Announcement • May 15
Mercury Laboratories Limited announces Annual dividend, payable on September 11, 2025 Mercury Laboratories Limited announced Annual dividend of INR 3.5000 per share payable on September 11, 2025, ex-date on August 06, 2025 and record date on August 06, 2025. New Risk • May 15
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.1% Last year net profit margin: 7.5% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.1% net profit margin). Market cap is less than US$100m (₹1.02b market cap, or US$11.9m). Announcement • May 14
Mercury Laboratories Limited, Annual General Meeting, Aug 13, 2025 Mercury Laboratories Limited, Annual General Meeting, Aug 13, 2025. Announcement • May 10
Mercury Laboratories Limited to Report Q4, 2025 Results on May 14, 2025 Mercury Laboratories Limited announced that they will report Q4, 2025 results on May 14, 2025 Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹9.94 (vs ₹10.30 in 3Q 2024) Third quarter 2025 results: EPS: ₹9.94 (down from ₹10.30 in 3Q 2024). Revenue: ₹201.0m (up 17% from 3Q 2024). Net income: ₹11.9m (down 3.5% from 3Q 2024). Profit margin: 5.9% (down from 7.2% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 05
Mercury Laboratories Limited to Report Q3, 2025 Results on Feb 12, 2025 Mercury Laboratories Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹4.17 (vs ₹12.56 in 2Q 2024) Second quarter 2025 results: EPS: ₹4.17 (down from ₹12.56 in 2Q 2024). Revenue: ₹184.0m (down 19% from 2Q 2024). Net income: ₹5.00m (down 67% from 2Q 2024). Profit margin: 2.7% (down from 6.6% in 2Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 09
Mercury Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024 Mercury Laboratories Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Buy Or Sell Opportunity • Oct 08
Now 30% overvalued after recent price rise Over the last 90 days, the stock has risen 8.6% to ₹1,118. The fair value is estimated to be ₹860, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. Buy Or Sell Opportunity • Sep 20
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to ₹1,034. The fair value is estimated to be ₹860, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. Upcoming Dividend • Sep 13
Upcoming dividend of ₹3.50 per share Eligible shareholders must have bought the stock before 20 September 2024. Payment date: 26 October 2024. Payout ratio is a comfortable 7.4% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). Buy Or Sell Opportunity • Aug 28
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 16% to ₹1,068. The fair value is estimated to be ₹853, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. Declared Dividend • Jul 26
Dividend of ₹3.50 announced Dividend of ₹3.50 is the same as last year. Ex-date: 20th September 2024 Payment date: 26th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 9.9% per year over the past 9 years and payments have been stable during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Jul 25
First quarter 2025 earnings released: EPS: ₹2.85 (vs ₹8.33 in 1Q 2024) First quarter 2025 results: EPS: ₹2.85 (down from ₹8.33 in 1Q 2024). Revenue: ₹168.3m (down 8.2% from 1Q 2024). Net income: ₹3.42m (down 66% from 1Q 2024). Profit margin: 2.0% (down from 5.5% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 17
Mercury Laboratories Limited to Report Q1, 2025 Results on Jul 24, 2024 Mercury Laboratories Limited announced that they will report Q1, 2025 results on Jul 24, 2024 Buy Or Sell Opportunity • Jul 11
Now 22% undervalued Over the last 90 days, the stock has risen 7.3% to ₹1,000. The fair value is estimated to be ₹1,277, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat. Announcement • May 30
Mercury Laboratories Limited Recommends Dividend for the Year 2023-24 Mercury Laboratories Limited recommended dividend @ 35% (INR 3.50 per share) on the Equity Share Capital for the year 2023-24 subject to approval of shareholders at an ensuing Annual General Meeting. Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹47.12 (vs ₹46.49 in FY 2023) Full year 2024 results: EPS: ₹47.12 (up from ₹46.49 in FY 2023). Revenue: ₹766.5m (up 1.7% from FY 2023). Net income: ₹56.5m (up 1.4% from FY 2023). Profit margin: 7.4% (in line with FY 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • May 23
Mercury Laboratories Limited to Report Fiscal Year 2024 Results on May 28, 2024 Mercury Laboratories Limited announced that they will report fiscal year 2024 results on May 28, 2024 Reported Earnings • Feb 13
Third quarter 2024 earnings released: EPS: ₹10.30 (vs ₹5.05 in 3Q 2023) Third quarter 2024 results: EPS: ₹10.30 (up from ₹5.05 in 3Q 2023). Revenue: ₹172.9m (up 6.5% from 3Q 2023). Net income: ₹12.4m (up 104% from 3Q 2023). Profit margin: 7.2% (up from 3.7% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹1,038, the stock trades at a trailing P/E ratio of 35.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years. Announcement • Feb 06
Mercury Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024 Mercury Laboratories Limited announced that they will report Q3, 2024 results on Feb 12, 2024 Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹1,238, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 115% over the past three years. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹913, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 86% over the past three years. Announcement • Nov 09
Mercury Laboratories Limited Announces Promotion of Saurabh Mittal as Chief Operating Officer Mercury Laboratories Limited announced that Mr. Saurabh Mittal has been promoted as Chief Operating Officer of the Company, Senior Management Personnel of the Company, with effect from November 08, 2023. Mr. Saurabh Mittal by qualification is an Engineer. He has rich experience of working with corporates for more than 13 years. He has rich experience and expertise in areas of Marketing, Human resources, Information and technology, system and process development for established as well as start-up organizations. Announcement • Sep 29
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31,2023 Merc Mercury Laboratories Limited announced that at its AGM held on September 27, 2023 declared a dividend of INR 3.50/- per equity share of INR 10/- each for the Financial Year ended March 31,2023. Upcoming Dividend • Sep 13
Upcoming dividend of ₹3.50 per share at 0.4% yield Eligible shareholders must have bought the stock before 20 September 2023. Payment date: 27 October 2023. Payout ratio is a comfortable 7.5% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%). Announcement • Aug 26
Mercury Laboratories Limited, Annual General Meeting, Sep 27, 2023 Mercury Laboratories Limited, Annual General Meeting, Sep 27, 2023, at 11:30 Indian Standard Time. Reported Earnings • Aug 06
First quarter 2024 earnings released: EPS: ₹8.33 (vs ₹12.19 in 1Q 2023) First quarter 2024 results: EPS: ₹8.33 (down from ₹12.19 in 1Q 2023). Revenue: ₹184.7m (up 4.9% from 1Q 2023). Net income: ₹10.00m (down 32% from 1Q 2023). Profit margin: 5.4% (down from 8.3% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹712, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 51% over the past three years. Reported Earnings • May 08
Full year 2023 earnings released: EPS: ₹46.49 (vs ₹30.72 in FY 2022) Full year 2023 results: EPS: ₹46.49 (up from ₹30.72 in FY 2022). Revenue: ₹770.5m (up 33% from FY 2022). Net income: ₹55.8m (up 51% from FY 2022). Profit margin: 7.2% (up from 6.4% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 06
Mercury Laboratories Limited Recommends Dividend for the Year 2022-23 Mercury Laboratories Limited recommended dividend @ 35% (INR 3.50 per share) on the Equity Share Capital for the year 2022-23 subject to approval of shareholders at an ensuing Annual General Meeting. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive Non Independent Director Janki Shah was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹669, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 103% over the past three years. Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹5.05 (vs ₹4.34 in 3Q 2022) Third quarter 2023 results: EPS: ₹5.05 (up from ₹4.34 in 3Q 2022). Revenue: ₹168.1m (up 7.8% from 3Q 2022). Net income: ₹6.07m (up 17% from 3Q 2022). Profit margin: 3.6% (up from 3.3% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 05
Mercury Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023 Mercury Laboratories Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improved over the past week After last week's 16% share price gain to ₹779, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 205% over the past three years. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improved over the past week After last week's 24% share price gain to ₹869, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 253% over the past three years. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹26.19 (vs ₹8.03 in 2Q 2022) Second quarter 2023 results: EPS: ₹26.19 (up from ₹8.03 in 2Q 2022). Revenue: ₹222.9m (up 65% from 2Q 2022). Net income: ₹31.4m (up 226% from 2Q 2022). Profit margin: 14% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹26.19 (vs ₹8.03 in 2Q 2022) Second quarter 2023 results: EPS: ₹26.19 (up from ₹8.03 in 2Q 2022). Revenue: ₹222.9m (up 65% from 2Q 2022). Net income: ₹31.4m (up 226% from 2Q 2022). Profit margin: 14% (up from 7.2% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 03
Mercury Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022 Mercury Laboratories Limited announced that they will report Q2, 2023 results on Nov 11, 2022 Announcement • Sep 28
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2022 Mercury Laboratories Limited at its annual general meeting held on September 27, 2022, approved a dividend of INR 3.50/- per equity share of INR 10/- each for the Financial Year ended March 31, 2022. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment improved over the past week After last week's 16% share price gain to ₹590, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 129% over the past three years. Upcoming Dividend • Sep 12
Upcoming dividend of ₹3.50 per share Eligible shareholders must have bought the stock before 19 September 2022. Payment date: 27 October 2022. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%). Announcement • Aug 27
Mercury Laboratories Limited, Annual General Meeting, Sep 27, 2022 Mercury Laboratories Limited, Annual General Meeting, Sep 27, 2022, at 11:30 Indian Standard Time. Reported Earnings • Aug 11
First quarter 2023 earnings released: EPS: ₹12.19 (vs ₹10.38 in 1Q 2022) First quarter 2023 results: EPS: ₹12.19 (up from ₹10.38 in 1Q 2022). Revenue: ₹180.9m (up 17% from 1Q 2022). Net income: ₹14.6m (up 17% from 1Q 2022). Profit margin: 8.1% (up from 8.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improved over the past week After last week's 17% share price gain to ₹502, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past three years. Announcement • May 27
Mercury Laboratories Limited Recommends Dividend for the Year 2022 Mercury Laboratories Limited at the Board of Director meeting held on May 26, 2022, the Board of Directors recommended dividend @ 35% (INR 3.50 per share) on the Equity Share Capital for the year 2021-22 subject to approval of shareholders at an upcoming Annual General Meeting. Announcement • May 19
Mercury Laboratories Limited to Report Q4, 2022 Results on May 26, 2022 Mercury Laboratories Limited announced that they will report Q4, 2022 results on May 26, 2022 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹576, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 77% over the past three years. Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improved over the past week After last week's 17% share price gain to ₹660, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 81% over the past three years. Reported Earnings • Oct 23
Second quarter 2022 earnings released: EPS ₹8.03 (vs ₹13.79 in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹134.7m (down 29% from 2Q 2021). Net income: ₹9.64m (down 42% from 2Q 2021). Profit margin: 7.2% (down from 8.7% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 19% per year. Upcoming Dividend • Sep 13
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 20 September 2021. Payment date: 28 October 2021. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.8%). Reported Earnings • Aug 11
First quarter 2022 earnings released: EPS ₹10.38 (vs ₹8.01 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹156.5m (up 17% from 1Q 2021). Net income: ₹12.5m (up 30% from 1Q 2021). Profit margin: 8.0% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Jun 24
Chief Financial Officer Enu Khandelwal has left the company During their tenure, earnings grew by 99% annually compared to the industry average of 59%. On the 22nd of June, Enu Khandelwal left the company after less than a year in the role. We don't have any record of a personal shareholding under Enu's name. Enu is the only executive to leave the company over the last 12 months. Reported Earnings • May 30
Full year 2021 earnings released: EPS ₹44.48 (vs ₹26.90 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹694.8m (up 21% from FY 2020). Net income: ₹53.4m (up 65% from FY 2020). Profit margin: 7.7% (up from 5.6% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 20% per year. Announcement • May 28
Mercury Laboratories Limited Recommends Dividend for Year Ended March 31, 2021 Mercury Laboratories Limited announced that at the meeting of Board of Director held on May 27, 2021, the Board of Directors has recommended dividend at 20% that is INR 2.00 per share for the year ended on March 31, 2021 subject to approval of shareholders at an upcoming Annual General Meeting in addition to interim dividend already declared by the Board for 2020 - 2021. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improved over the past week After last week's 16% share price gain to ₹661, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years. Upcoming Dividend • Feb 15
Upcoming Dividend of ₹1.50 Per Share Will be paid on the 13th of March to those who are registered shareholders by the 22nd of February. The trailing yield of 0.3% is below the top quartile of Indian dividend payers (1.9%), and is lower than industry peers (0.7%). Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS ₹16.96 (vs ₹12.73 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹187.2m (up 20% from 3Q 2020). Net income: ₹20.4m (up 33% from 3Q 2020). Profit margin: 11% (up from 9.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 17% per year. Announcement • Feb 03
Mercury Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021 Mercury Laboratories Limited announced that they will report Q3, 2021 results on Feb 11, 2021 Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improved over the past week After last week's 20% share price gain to ₹584, the stock is trading at a trailing P/E ratio of 18.5x, up from the previous P/E ratio of 15.4x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 32%. Is New 90 Day High Low • Dec 30
New 90-day high: ₹510 The company is up 28% from its price of ₹400 on 29 September 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Nov 09
New 90-day high: ₹473 The company is up 27% from its price of ₹374 on 11 August 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Valuation Update With 7 Day Price Move • Nov 09
Market bids up stock over the past week After last week's 18% share price gain to ₹473, the stock is trading at a trailing P/E ratio of 17.8x, up from the previous P/E ratio of 15.1x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 14%. Valuation Update With 7 Day Price Move • Nov 05
Market bids up stock over the past week After last week's 22% share price gain to ₹464, the stock is trading at a trailing P/E ratio of 17.5x, up from the previous P/E ratio of 14.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 6.4%. Announcement • Oct 27
Mercury Laboratories Limited to Report Q2, 2021 Results on Nov 06, 2020 Mercury Laboratories Limited announced that they will report Q2, 2021 results on Nov 06, 2020 Is New 90 Day High Low • Oct 12
New 90-day high: ₹453 The company is up 50% from its price of ₹302 on 13 July 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period. Announcement • Oct 01
Mercury Laboratories Limited Appoints Janki R Shah as Director Mercury Laboratories Limited appointed Janki R Shah as Director of the Company at the Annual General Meeting of the Company held on September 29, 2020.